Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Maximilian Stahl; Michelle DeVeaux; Pau Montesinos; Raphaël Itzykson; Ellen K. Ritchie; Mikkael A. Sekeres; John Barnard; Nikolai A. Podoltsev; Andrew Brunner; Rami S. Komrokji; Vijaya R. Bhatt; Aref Al-Kali; Thomas Cluzeau; Valeria Santini; Gail J. Roboz; Pierre Fenaux; Mark Litzow; Amir T. Fathi; Sarah Perreault; Tae Kon Kim; Thomas Prebet; Norbert Vey; Vivek Verma; Ulrich Germing; Juan Bergua; Josefina Serrano; Steven D. Gore; Amer M. Zeidan

doi:10.1080/10428194.2018.1468893

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

Maximilian Stahl, Michelle DeVeaux, Pau Montesinos, Raphaël Itzykson, Ellen K. Ritchie, Mikkael A. Sekeres, John Barnard, Nikolai A. Podoltsev, Andrew Brunner, Rami S. Komrokji, Vijaya R. Bhatt, Aref Al-Kali, Thomas Cluzeau, Valeria Santini, Gail J. Roboz, Pierre Fenaux, Mark Litzow, Amir T. Fathi, Sarah Perreault, Tae Kon KimThomas Prebet, Norbert Vey, Vivek Verma, Ulrich Germing, Juan Bergua, Josefina Serrano, Steven D. Gore, Amer M. Zeidan

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	246-249
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	60
Issue number	1
DOIs	https://doi.org/10.1080/10428194.2018.1468893
State	Published - Jan 2 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2018.1468893

Cite this

Stahl, M., DeVeaux, M., Montesinos, P., Itzykson, R., Ritchie, E. K., Sekeres, M. A., Barnard, J., Podoltsev, N. A., Brunner, A., Komrokji, R. S., Bhatt, V. R., Al-Kali, A., Cluzeau, T., Santini, V., Roboz, G. J., Fenaux, P., Litzow, M., Fathi, A. T., Perreault, S., ... Zeidan, A. M. (2019). Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 60(1), 246-249. https://doi.org/10.1080/10428194.2018.1468893

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. / Stahl, Maximilian; DeVeaux, Michelle; Montesinos, Pau et al.
In: Leukemia and Lymphoma, Vol. 60, No. 1, 02.01.2019, p. 246-249.

Research output: Contribution to journal › Letter › peer-review

Stahl, M, DeVeaux, M, Montesinos, P, Itzykson, R, Ritchie, EK, Sekeres, MA, Barnard, J, Podoltsev, NA, Brunner, A, Komrokji, RS, Bhatt, VR, Al-Kali, A, Cluzeau, T, Santini, V, Roboz, GJ, Fenaux, P, Litzow, M, Fathi, AT, Perreault, S, Kim, TK, Prebet, T, Vey, N, Verma, V, Germing, U, Bergua, J, Serrano, J, Gore, SD & Zeidan, AM 2019, 'Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia', Leukemia and Lymphoma, vol. 60, no. 1, pp. 246-249. https://doi.org/10.1080/10428194.2018.1468893

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA et al. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma. 2019 Jan 2;60(1):246-249. doi: 10.1080/10428194.2018.1468893

@article{d824ea7bd6d94d039dd88df9a66fa493,

title = "Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia",

author = "Maximilian Stahl and Michelle DeVeaux and Pau Montesinos and Rapha{\"e}l Itzykson and Ritchie, {Ellen K.} and Sekeres, {Mikkael A.} and John Barnard and Podoltsev, {Nikolai A.} and Andrew Brunner and Komrokji, {Rami S.} and Bhatt, {Vijaya R.} and Aref Al-Kali and Thomas Cluzeau and Valeria Santini and Roboz, {Gail J.} and Pierre Fenaux and Mark Litzow and Fathi, {Amir T.} and Sarah Perreault and Kim, {Tae Kon} and Thomas Prebet and Norbert Vey and Vivek Verma and Ulrich Germing and Juan Bergua and Josefina Serrano and Gore, {Steven D.} and Zeidan, {Amer M.}",

note = "Funding Information: The authors acknowledge the Frederick A. DeLuca Foundation for financial support.",

year = "2019",

month = jan,

day = "2",

doi = "10.1080/10428194.2018.1468893",

language = "English (US)",

volume = "60",

pages = "246--249",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

AU - Stahl, Maximilian

AU - DeVeaux, Michelle

AU - Montesinos, Pau

AU - Itzykson, Raphaël

AU - Ritchie, Ellen K.

AU - Sekeres, Mikkael A.

AU - Barnard, John

AU - Podoltsev, Nikolai A.

AU - Brunner, Andrew

AU - Komrokji, Rami S.

AU - Bhatt, Vijaya R.

AU - Al-Kali, Aref

AU - Cluzeau, Thomas

AU - Santini, Valeria

AU - Roboz, Gail J.

AU - Fenaux, Pierre

AU - Litzow, Mark

AU - Fathi, Amir T.

AU - Perreault, Sarah

AU - Kim, Tae Kon

AU - Prebet, Thomas

AU - Vey, Norbert

AU - Verma, Vivek

AU - Germing, Ulrich

AU - Bergua, Juan

AU - Serrano, Josefina

AU - Gore, Steven D.

AU - Zeidan, Amer M.

N1 - Funding Information: The authors acknowledge the Frederick A. DeLuca Foundation for financial support.

PY - 2019/1/2

Y1 - 2019/1/2

UR - http://www.scopus.com/inward/record.url?scp=85049603735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049603735&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1468893

DO - 10.1080/10428194.2018.1468893

M3 - Letter

C2 - 29963936

AN - SCOPUS:85049603735

SN - 1042-8194

VL - 60

SP - 246

EP - 249

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this